We found that similarly to TEVs, the PD-L1 levels were higher in resistant cells and after IL-1β stimulation than the control cells, thus suggesting that TEVs and cancer cells, from which they are released, may synergistically contribute to tumor immune evasion. The gene discussed is IL1B; the disease is cancer.